August 31, 2017

The CAR-T Revolution: Gilead’s $12B Acquisition of Kite Pharma & FDA Approval of Novartis’ Kymriah Signal Tipping Point for Promising Cancer Immunotherapies

[vc_row][vc_column][vc_column_text] Gilead Sciences has ended its M&A moratorium with an $11.9B all-cash acquisition of CAR-T Cell Therapy pioneers Kite Pharma. Kite’s leading drug Axi-Cel is expected […]
September 14, 2016

Cancer Immunotherapy: A Developmental Timeline & Examination of the Prior Art Paradox

[vc_row][vc_column][vc_column_text]The American Society of Clinical Oncology (ASCO) recently named cancer immunotherapy as the 2016 Advance of the Year, with President Dr. Julie Vose noting that “no […]